Vinergy Resources Ltd (CSE:VIN , OTCQB:VNNYF), in conjunction with its proposed acquisition of MJ Biopharma announces that, as a part of the Company's strategy to develop a lab for research and development products that test and identify specific cannabinoid isolates for targeted therapeutic purposes, it has appointed John Simon to the Company's Scientific Advisory Board. John has a Bachelor of Science from the University of Alberta, is a senior member of the American Society for Quality, a Certified Quality Auditor (CQA), a Registered Quality Assurance Professional in Good Laboratory Practice (RQAP-GLP) and maintains Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society.
Through John's consultancy practice, he assists companies with both site licenses and product licenses. He has helped companies obtain, renew and maintain in good standing Drug Establishment Licenses (DEL); Medical Device Establishment Licenses (MDEL); Natural and Non-prescription Site Licenses (NNHPD); and Licenses to Cultivate and Distribute under the Marijuana for Medical Purposes Regulations (MMPR) (now under the ACMPR). "With John's substantial background in QA and regulatory affairs specific to drug development and the cannabis industry, he will be a key asset in driving our cannabis product and technology initiatives," said Mr.Kent Deuters, CEO of MJ Biopharma.
Vinergy Resources also announced this week a major breakthrough while conducting research and development on oral cannabinoid complex (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinol (CBN) and Terpenes) delivery strips and controlled time-release capsule technology. This novel approach will be the basis for several products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of the cannabinoid complex into the body.